RVLPQ (RVL Pharmaceuticals) Payments of Debt: $-6.23 Mil (TTM As of Jun. 2023)


RVLPQ RVL Pharmaceuticals PLC RVLPQ
12 GF Score
Price $0.00
View Full Analysis

What is RVL Pharmaceuticals Payments of Debt?

RVL Pharmaceuticals RVLPQ -90.00% 12 Payments of Debt is $-6.23 Mil as of Jun. 2023. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

RVL Pharmaceuticals's Payments of Debt for the three months ended in Jun. 2023 was $-0.44 Mil.

RVL Pharmaceuticals's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2023 was $-6.23 Mil.

RVL Pharmaceuticals Payments of Debt Related Terms

RVL Pharmaceuticals Payments of Debt Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals Payments of Debt Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Payments of Debt
Get a 7-Day Free Trial -57.22 -3.22 -50.13 -222.31 -2.71

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -0.61 -0.29 -4.88 -0.44
RVLPQ
12GF Score
RVL Pharmaceuticals PLC RVLPQ
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RVL Pharmaceuticals Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-6.23 Mil mean?
RVL Pharmaceuticals (RVLPQ) has a Payments of Debt of $-6.23 Mil as of Jun. 2023. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on RVL Pharmaceuticals and its competitors.
Is RVL Pharmaceuticals' Payments of Debt too high?
RVL Pharmaceuticals' current Payments of Debt is $-6.23 Mil. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' Payments of Debt compare to SNPX and THAR?
RVL Pharmaceuticals' Payments of Debt of $-6.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on RVL Pharmaceuticals and its competitors. RVL Pharmaceuticals's current Payments of Debt is $-6.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current Payments of Debt of $-6.23 Mil. The current Payments of Debt is $-6.23 Mil. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Payments of Debt is $-6.23 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score

Get the complete analysis for RVLPQ

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price